Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization
Abstract Breast cancer became the most prevalent malignancy among women, and HER2 expression status is critical for treatment decisions. With the emergence of ADC drugs, HER2 low-expressing patients who previously did not respond well to traditional anti-HER2 therapies may now benefit. In this study...
Saved in:
Main Authors: | Jingmin Zhong, Beibei Gao, Qingjie Wang, Jun He, Danjv Luo, Chen Zhang, Jun Fan, Xiu Nie |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Diagnostic Pathology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13000-024-01594-y |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Evaluation of CD10 and HER2 Immunohistochemical Markers in Urothelial Carcinoma of Urinary Bladder
by: Khalid W. Abdulfattah Khattab, et al.
Published: (2024-12-01) -
Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01) -
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
by: Femke A. I. Ehlers, et al.
Published: (2025-01-01) -
Ultrafast dynamic contrast-enhanced breast MRI with quantitative perfusion parameters in differentiating breast cancer: a study focusing on triple-negative and HER2 positive breast cancer
by: Guo Haodong, et al.
Published: (2025-01-01) -
Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01)